Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...

Analyst Price Forecast Suggests 9.53% Downside As of ... The firm decreased its portfolio allocation in BMY by 91.87% over ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

From these selections, we ranked each stock based on the total number of hedge fund ... On September 29, BMO Capital raised ...

BofA raised the firm’s price target on Bristol Myers (BMY) to $60 from $55 and keeps a Neutral rating on the shares. Bristol reported ...